- Home
- Equipment
- usa colorado
- clinical program
Show results for
Refine by
Clinical Program Equipment & Supplies In In Usa Colorado
58 equipment items found
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific T-cell response, including both CD4+ and CD8+ ...
Manufactured by:Aposcience AG based inVienna, AUSTRIA
Discussions are underway for the design of a clinical program in this indication together with a manufacturer of catheter devices suitable for direct myocardial injection of APO-1 ...
Manufactured by:AOBiome Therapeutic, LLC based inCambridge, MASSACHUSETTS (USA)
We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,000 patients have been enrolled in our clinical trials since 2016. All of those patients except for 28 in our open label pediatric study have been enrolled in randomized double-blind placebo controlled ...
Manufactured by:BioXcel Therapeutics, Inc. based inNew Haven, CONNECTICUT (USA)
BXCL501 is our most advanced neuroscience clinical program. BXCL501 is a proprietary, sublingual film formulation of dexmedetomidine, a selective alpha-2 receptor agonist. It is being investigated for at-home use for the acute treatment of agitation in bipolar and schizophrenia patients, for agitation in Alzheimer’s disease, and as an adjunctive treatment ...
by:Oligomerix, Inc. based inWhite Plains, NEW YORK (USA)
While Alzheimer’s is the largest tauopathy, other tauopathies are rare diseases that present accelerated regulatory pathways and significant near-term commercial opportunities. These rare diseases shown in Chart A below have a tau etiology similar to AD. Oligomerix’s 1st clinical program focuses on demonstrating safety and efficacy of our lead ...
Manufactured by:Elixir Medical Corporation based inMilpitas, CALIFORNIA (USA)
Sirolimus is the most widely known mTOR inhibitor with a well-established safety and effectiveness profile in various treatment applications: Drug-eluting stents, Transplant, Oncology. Novolimus and Sirolimus have been studied as part of Elixir Medical’s Clinical Programs. These clinical trials for DynamX™, DESyne®, ...
Manufactured by:Microbion Corporation based inBozeman, MONTANA (USA)
Microbion has two Phase 2 clinical programs in diabetic foot ulcer infection and orthopedic implant infection. In addition, preclinical programs are under development for multiple therapeutic indications, including the treatment of serious respiratory ...
Manufactured by:MD Spiro, A MicroDirect Company based inLewiston, MAINE (USA)
The CO Check+ is an innovative smoking cessation tool designed specifically for use in smoking cessation programs and clinics. One single breath of expiration into the CO Check+ provides instant results in PPM and %COHb via the large, easy-to-read ...
by:Align Technology, Inc. based inTempe, ARIZONA (USA)
The Invisalign system is the most advanced clear aligner system in the world. Backed by two decades of innovation, the Invisalign system has helped bring smiles to over 9.6 million people including over 2.4 million ...
Manufactured by:Daiichi Sankyo Company Limited based inTokyo, JAPAN
Oral, once-daily, direct factor Xa (pronounced “Ten A”) inhibitor. More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, which is comprised of more than 10 RCTs (randomized, controlled trials), non-interventional studies and registries, including completed, ongoing and future research. ...
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
CT-132 is under development as a clinically-validated digital program for ...
Manufactured by:Ito Co., Ltd. based inKawaguchi City, Saitama, JAPAN
Electrotherapy Device with 2 Independent Channels and Body Diagram ...
Manufactured by:Ito Co., Ltd. based inKawaguchi City, Saitama, JAPAN
Electrotherapy Device with 4 Independent Channels and Body Diagram ...
Manufactured by:BioFactura, Inc. based inFrederick, MARYLAND (USA)
BioFactura develops and commercializes high-value biosimilars (i.e., follow-on biologics or generic biopharmaceuticals) using its patented StableFastTM Biomanufacturing Platform, the optimal choice for bringing these drug to market with faster, lower cost, superior-quality manufacture. The global biosimilars market is projected to grow from $4.5B in 2017 to over $23B by 2023 with a Compound ...
by:Verb Biotics based inBoston, MASSACHUSETTS (USA)
Yso1 is a clinical stage development program aiming at harnessing the potential of Christensenella minuta as a groundbreaking biotherapy to treating obesity and metabolic disorders. The goal of our disruptive approach is to return to obese patients christensenella, which have the unique ability to repair the unbalanced microbiome, thereby restoring impaired key ...
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
Clickadian is under development as a clinically-validated fully digital program for ...
by:GW Pharmaceuticals plc based inCambridge, UNITED KINGDOM
Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU; nabiximols in the US) is an oromucosal spray of a formulated cannabis extract that contains the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD), as well as specific minor cannabinoids and other non-cannabinoid components. We developed Sativex® to be administered as an oromucosal spray, ...
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
Clickheart is under development as a clinically-validated digital program for acute coronary ...
by:Click Therapeutics, Inc based inNew York, NEW YORK (USA)
CT-161 is under development as a clinically-validated digital program for overactive ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
Antibody-drug conjugates (ADCs) combine the targeted binding specificity and pharmacological advantages of monoclonal antibodies with the potency advantages of small molecule chemotherapy agents via conjugation with chemical linkers. With 10 approved products and a large and growing list of programs in clinical and pre-clinical development, ADCs ...